Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US fate of Auxilium drug in penis disease expected by early September

This article was originally published in Scrip

Executive Summary

Shares of Auxilium Pharmaceuticals got a slight 1.47% bump on 27 December after the company said the US FDA has accepted for review the firm's supplemental biologics license application (sBLA) for Xiaflex (collagenase clostridium histolyticum or CCH) as a treatment for Peyronie's disease, a rare progressive condition in which collagen plaque or scar tissue develops on the shaft of the penis, hardening and reducing flexibility, thus causing pain and forcing the penis to bend or arc during erection, often preventing intercourse.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC019895

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel